Trials / Completed
CompletedNCT02443883
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 164 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study was to evaluate the safety and pharmacokinetics of administering various dose regimens of ramucirumab in participants with advanced gastric cancer whose disease has progressed during or following prior chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ramucirumab | Administered IV |
Timeline
- Start date
- 2015-07-07
- Primary completion
- 2016-11-18
- Completion
- 2019-06-05
- First posted
- 2015-05-14
- Last updated
- 2020-06-29
- Results posted
- 2018-03-13
Locations
45 sites across 12 countries: United States, Argentina, Australia, France, Hungary, New Zealand, Poland, Romania, Russia, Slovakia, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT02443883. Inclusion in this directory is not an endorsement.